Bristol-Myers Squibb’s Virology Products in 4Q17
The virology portfolio
Bristol-Myers Squibb’s (BMY) virology portfolio includes Hepatitis B (or HBV) products, Hepatitis C (or HCV) products, HIV products, and other virology products classified under the company’s established brands.
The chart below compares the revenues for the Hepatitis C franchise and key virology products from its Hepatitis B and HIV portfolio since 1Q16.
Interested in ABBV? Don't miss the next report.
Receive e-mail alerts for new research on ABBV
Hepatitis B products
Baraclude, which is BMY’s only Hepatitis B product, reported revenues of $233.0 million in 4Q17 for a 21.0% decrease compared to revenues of $296.0 million during 4Q16. For fiscal 2017, Baraclude reported revenues of $1.0 billion, which was a 12.0% decrease compared to revenues of $1.2 billion during 2016.
Baraclude is losing the market share to competition from other drugs including Teva Pharmaceuticals’ (TEVA) entecavir tablets.
Hepatitis C products
Bristol-Myers Squibb’s (BMY) Hepatitis C products include the drugs Daklinza and Sunvepra. These drugs reported combined revenues of $59.0 million during 4Q17, a decline of ~74.0% in revenues compared $226.0 million during 4Q16.
For fiscal 2017, the combined revenues for Hepatitis C products totaled $406.0 million, a 74.0% decline compared to $1.6 billion during 2016.
Bristol-Myers Squibb’s HIV products include Reyataz and Sustiva. Reyataz reported revenues of $143.0 million during 4Q17, which was a 31.0% decrease compared to 4Q16. Sustiva reported revenues of $174.0 million during 4Q17 for a 29.0% decrease compared to 4Q16.
For fiscal 2017, Reyataz’s revenues totaled $698.0 million, which was a 23.0% decrease compared to 2016. Sustiva’s revenues totaled $729.0 million during 2017, which was a 32.0% decrease compared to 2016. The decline in revenues was driven by the competition from other HIV products in the market.